AML On The Go - Selective Inhibition of FLT3 by Gilteritinib

Sdílet
Vložit
  • čas přidán 4. 12. 2017
  • Selective Inhibition of FLT3 by Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia: A Multicenter, First-in-human, Open Label, Phase 1-2 Study - pub. 11/14/17
    AMLOTG21

Komentáře •